Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 197, Issue -, Pages 170-179Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2015.06.076
Keywords
DPP4; Incretin; GLP-1; Cardiometabolic disease; Diabetes
Categories
Funding
- AHA [15SDG25700381, 13POST17210033]
- NSFC [81101553/H1604]
Ask authors/readers for more resources
Cardiometabolic disorders including obesity, diabetes and cardiovascular disease are among the most severe health problems worldwide. DPP4 enzymatic inhibitors were first developed as anti-diabetic reagents which preserve incretin hormones and promote post-prandial insulin secretion. It's been shown in animal studies that incretin-based therapy has a beneficial effect on cardiovascular disease. Recent studies demonstrated novel non-catalytic functions of DPP4 that may play a role in cardiometabolic disease. Although the role of DPP4 inhibition-mediated incretin effects has been well-reviewed, little information of its incretin-independent actions was introduced in cardiometabolic disease. In the current review, we will summarize the catalytic dependent and independent effects of DPP4 inhibition on cardiometabolic disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available